---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-020586"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:37:05.700599+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma presents CDI-988 data at ICAR 2026; Phase 1b norovirus study fully enrolled in stage 1

## Summary
- CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.
- Phase 1b study fully enrolled first cohort to assess infectivity of GII.2 Snow Mountain Virus inoculum.
- CDI-988 is first oral direct-acting antiviral for norovirus; targets conserved 3CL protease across strains.
- FDA Fast Track designation granted for CDI-988 for norovirus treatment and prophylaxis.
- No approved treatments or vaccines for norovirus; $60 billion annual economic burden.

## SEC filing metadata
- accession: 0001493152-26-020586
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/0001493152-26-020586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-020586
- JSON: https://secwatch.observer/filing/0001493152-26-020586.json
- Plain text: https://secwatch.observer/filing/0001493152-26-020586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.